NCT02932254View on ClinicalTrials.gov

Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Neuromuscular Blockade
Interventions
DRUG

Magnesium Sulfate

After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).

DRUG

Saline

After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).

Trial Locations (1)

22271042

Hospital Federal de Bonsucesso, Rio de Janeiro

All Listed Sponsors
lead

Universidade Federal do Rio de Janeiro

OTHER

NCT02932254 - Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex | Biotech Hunter | Biotech Hunter